ReviewFrontiers in neuroscience2026
Advances in biomarkers for diagnosing and prognosticating disorders of consciousness.
Review in Frontiers in neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Disorders of Consciousness (DoC) resulting from brain injury comprise a spectrum of clinical syndromes, where the level of impairment varies considerably depending on lesion location, etiology, severity, and individual patient factors. These differences substantially influence both rehabilitation strategies and long-term prognosis. Current diagnostic assessment relies primarily on behavioral scales, supplemented by electrophysiological and neuroimaging studies; however, these approaches remain limited in objectivity, sensitivity, and accessibility. There is therefore a clinical need for biologically informative biomarkers to improve diagnostic precision and prognostic stratification in DoC. This narrative review synthesizes recent advances in biomarker research, encompassing proteomic, metabolomic, and microRNAs (miRNAs) signatures, across multiple biological specimens. We evaluate the findings spanning exploratory to validation stages, and discuss their translational potential, providing a valuable reference for future large-scale, multicenter investigations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.